The magnitude and clinical implication of SERPINA1 and FHIT methylation in non-small cell lung cancer based on analysis of TCGA database

doi:10.16138/j.1673-6087.2021.02.008

Abstract

Abstract:

Objective To investigate the significance of serine protease inhibitor A1 (SERPINA1) and fragile histidine triad(FHIT) methylation in non-small cell lung cancer(NSCLC) patients based on analysis of TCGA database. Methods The information of SERPINA1/FHIT gene expression, methylation information and associated clinical manifestations were retrieved from TCGA database and analyzed both online and offline. The link between the magnitude of SERPINA1 and FHIT methylation and parameters, such as age, gender, histological-type, smoking history and TNM stage, was probed. Results The expression level of SERPINA1 was higher in tumor tissues other than adjacent non-tumor lung tissues in both lung adenocarcinoma (LUAD) and lung squamous-cell cancer (LUSC) (P<0.05). Hypomethylation of SERPINA1 was mostly observed in LUAD tissue of male patients or individuals with metastasis(P<0.05). The methylation of SERPINA1 and FHIT methylation was not affected by smoking history, nor was it associated with TNM stage or overall survival. Conclusions SERPINA1 and FHIT methylation might play a role in lung cancer. Hypomethylation in SERPINA1 is related with metastasis of LUAD.

Key words: Non-small cell lung cancer, Epigenetic, Methylation, Serine protease inhibitor A1, Fragile histidine triad, Cigarette smoking

CLC Number:

R743.2

WANG Jiahui, LI Ning, SUN Xianwen, LIN Yingni, DING Yongjie, SONG Hejie, LI Qingyun. The magnitude and clinical implication of SERPINA1 and FHIT methylation in non-small cell lung cancer based on analysis of TCGA database[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(02): 103-107.

Figures/Tables 5

References 21

[1]	孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11.
[2]	Mouronte-Roibás C, Leiro-Fernández V, Ruano-Raviña A, et al. Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study[J]. Respir Res, 2019, 20(1): 198. doi: 10.1186/s12931-019-1155-2 URL
[3]	Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, et al. Do FHIT gene alterations play a role in human solid tumors[J]?. Asia Pac J Clin Oncol, 2018, 14(5): e214-e223.
[4]	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102. doi: 10.1093/nar/gkx247 URL
[5]	Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data[J]. PLoS One, 2014, 9(9): e106397. doi: 10.1371/journal.pone.0106397 URL
[6]	Koch A, De Meyer T, Jeschke J, et al. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data[J]. BMC Genomics, 2015, 16(1): 636. doi: 10.1186/s12864-015-1847-z URL
[7]	Esteller M. Epigenetics in cancer[J]. N Engl J Med, 2008, 358(11): 1148-1159. doi: 10.1056/NEJMra072067 URL
[8]	罗汶鑫, 李为民. 肺癌的表观遗传学研究进展及其临床意义[J]. 中国呼吸与危重监护杂志, 2018, 17(3): 313-318.
[9]	Portela A, Esteller M. Epigenetic modifications and human disease[J]. Nat Biotechnol, 2010, 28(10): 1057-1068. doi: 10.1038/nbt.1685 pmid: 20944598
[10]	Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma[J]. PLoS One, 2011, 6(6): e21443. doi: 10.1371/journal.pone.0021443 URL
[11]	El-Akawi ZJ, Abu-Awad AM, Sharara AM, et al. The importance of alpha-1 antitrypsin (α-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients[J]. Neuro Endocrinol Lett, 2010, 31(1): 113-116.
[12]	Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function[J]. Am J Respir Crit Care Med, 2012, 185(4): 373-381. doi: 10.1164/rccm.201108-1382OC URL
[13]	Jaberie H, Hosseini SV, Naghibalhossaini F. Evaluation of alpha 1-antitrypsin for the early diagnosis of colorectal cancer[J]. Pathol Oncol Res, 2020, 26(2): 1165-1173. doi: 10.1007/s12253-019-00679-0 pmid: 31183614
[14]	Frenzel E, Wrenger S, Brügger B, et al. α1-Antitrypsin combines with plasma fatty acids and induces angiopoietin-like protein 4 expression[J]. J Immunol, 2015, 195(8): 3605-3616. doi: 10.4049/jimmunol.1500740 pmid: 26363050
[15]	Ercetin E, Richtmann S, Delgado BM, et al. Clinical significance of SERPINA1 gene and its encoded alpha1-antitrypsin protein in NSCLC[J]. Cancers (Basel), 2019, 11(9): 1306. doi: 10.3390/cancers11091306 URL
[16]	Song X, Tian Z, Wang S, et al. Restoration of fragile histidine triad(FHIT) expression inhibits cell growth and induces apoptosis in cutaneous T-cell lymphoma cell line[J]. Cancer Invest, 2010, 28(10): 1019-1023. doi: 10.3109/07357900902849608 URL
[17]	Czarnecka KH, Migdalska-Sęk M, Domańska D, et al. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer[J]. Int J Oncol, 2016, 49(3): 1175-1184. doi: 10.3892/ijo.2016.3610 pmid: 27572663
[18]	Wu X, Wu G, Yao X, et al. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review[J]. Drug Des Devel Ther, 2016, 10: 699-709.
[19]	Geradts J, Fong KM, Zimmerman PV, et al. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features[J]. Br J Cancer, 2000, 82(6): 1191-1197. doi: 10.1054/bjoc.1999.1062 URL
[20]	de Fraipont F, Moro-Sibilot D, Michelland S, et al. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer[J]?. Lung Cancer, 2005, 50(2): 199-209. pmid: 16043258
[21]	Maruyama R, Sugio K, Yoshino I, et al. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma[J]. Cancer, 2004, 100(7): 1472-1477. doi: 10.1002/cncr.20144 URL

项目	肺腺癌		肺鳞癌
项目	SERPINA1（n=458）	FHIT（n=458）	SERPINA1（n=370）	FHIT（n=74）
年龄(岁)	65.12±10.15		67.58±8.73	69.31±8.91
性别[n(%)]
男性	214(46.72)		274(74.05)	52(70.27)
女性	244(53.28)		96(25.95)	22(29.73)
吸烟史[n(%)]	322(70.31)		319(86.22)	59(79.73)
是否死亡（否/是）	293/165		210/160	33/41
人种（白色人种/其他）	353/105		274/96	58/16
TNM分期[n(%)]
Ⅰ~Ⅱ期	364(79.48)		309(83.51)	61(82.43)
Ⅲ期	74(16.16)		57(15.40)	12(16.22)
Ⅳ期	20(4.37)		4(1.08)	1(1.35)